UY33789A - COMBINATION THAT INCLUDES A FAMILY DERIVATIVE OF COMBRETASTATINAS AND CETUXIMAB - Google Patents

COMBINATION THAT INCLUDES A FAMILY DERIVATIVE OF COMBRETASTATINAS AND CETUXIMAB

Info

Publication number
UY33789A
UY33789A UY0001033789A UY33789A UY33789A UY 33789 A UY33789 A UY 33789A UY 0001033789 A UY0001033789 A UY 0001033789A UY 33789 A UY33789 A UY 33789A UY 33789 A UY33789 A UY 33789A
Authority
UY
Uruguay
Prior art keywords
cetuximab
combination
combretastatinas
family derivative
derivative
Prior art date
Application number
UY0001033789A
Other languages
Spanish (es)
Inventor
Chantal Carrez
Brigitte Demers
Yvette Ruffin
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33789A publication Critical patent/UY33789A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación farmacéutica que comprende un derivado de la familia de las combretastatinas, tal como la ombrabulina, que puede estar en forma de base o en forma de una sal farmacéuticamente aceptable, y cetuximab.The invention relates to a pharmaceutical combination comprising a derivative of the combretastatin family, such as ombrabulin, which may be in the form of a base or in the form of a pharmaceutically acceptable salt, and cetuximab.

UY0001033789A 2010-12-09 2011-12-09 COMBINATION THAT INCLUDES A FAMILY DERIVATIVE OF COMBRETASTATINAS AND CETUXIMAB UY33789A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1060293A FR2968557A1 (en) 2010-12-09 2010-12-09 ANTITUMOR COMBINATION COMPRISING A DRIFT OF THE COMBRETASTATIN FAMILY AND THE CETUXIMAB

Publications (1)

Publication Number Publication Date
UY33789A true UY33789A (en) 2012-07-31

Family

ID=43837735

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033789A UY33789A (en) 2010-12-09 2011-12-09 COMBINATION THAT INCLUDES A FAMILY DERIVATIVE OF COMBRETASTATINAS AND CETUXIMAB

Country Status (5)

Country Link
AR (1) AR084169A1 (en)
FR (1) FR2968557A1 (en)
TW (1) TW201306833A (en)
UY (1) UY33789A (en)
WO (1) WO2012076688A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889530A1 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
US20170128592A1 (en) * 2015-10-01 2017-05-11 Indian Institute Of Technology, Bombay Targeted polymeric nano-complexes as drug delivery system
CN112225673B (en) * 2020-11-13 2022-08-02 义乌市华耀医药科技有限公司 Amino combretastatin derivative and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
BR9909393A (en) 1998-04-03 2000-12-26 Ajinomoto Kk Antitumor agent, use of a stilbene derivative and a platinum coordination compound, and, process for the treatment or improvement of a tumor
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
WO2003000290A1 (en) 2001-06-25 2003-01-03 Ajinomoto Co., Inc. Antitumor agents
FR2838437B1 (en) 2002-04-11 2004-06-04 Aventis Pharma Sa PROCESSES FOR THE PREPARATION OF COMBRETASTATINS
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
FR2895258B1 (en) 2005-12-22 2008-03-21 Aventis Pharma Sa COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS
WO2009076170A2 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2009103076A1 (en) * 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2945210B1 (en) * 2009-05-07 2011-07-01 Sanofi Aventis ANTITUMOR COMBINATION COMPRISING AVE8062 AND SORAFENIB

Also Published As

Publication number Publication date
AR084169A1 (en) 2013-04-24
TW201306833A (en) 2013-02-16
WO2012076688A1 (en) 2012-06-14
FR2968557A1 (en) 2012-06-15

Similar Documents

Publication Publication Date Title
CL2014003136A1 (en) New diazaespirocicloalcanos and azaespirocicloalcanos; Pharmaceutical composition that contains them and uses.
CL2014002093A1 (en) Piperidinopyrimidine derivative compounds; pharmaceutical composition that includes them; Use in the treatment of viral infections.
CO6980625A2 (en) Compositions that generate peracids
CR20130406A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HUMAN ANTIBODIES AGAINST PCSK9
DK2694038T3 (en) PHARMACEUTICAL COMPOSITION
DK2912074T3 (en) DERMAL INJECTABLE STERILE COMPOSITION
BR112014010164A2 (en) hard tissue implant
MX2021004211A (en) Vaccine compositions.
CR20120008A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
CL2014000447A1 (en) Compounds derived from substituted pyridine and pyrimidine, quinurenine-3-monooxygenase mediators; pharmaceutical compositions comprising them; and use in the treatment of a neurodegenerative pathology, such as huntington's disease.
ITTO20110641A1 (en) PHARMACEUTICAL COMPOSITIONS AND TREATMENT METHODS
PE20151435A1 (en) LAQUINIMOD TO REDUCE THALAMIC DAMAGE IN MULTIPLE SCLEROSIS
HN2011003403A (en) HETEROCICLIC SULFONAMIDS, USES AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
CO6801754A2 (en) A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide
CL2013002905A1 (en) Pharmaceutical composition comprising fimasartan, a salt, solvate or hydrate thereof and amlodipine, an isomer, salt, solvate or hydrate thereof; Use in the treatment of hypertension and cardiovascular diseases.
CO6920289A2 (en) Topical ophthalmic pharmaceutical composition containing regorafenib.
CO7010828A2 (en) Pharmaceutical preparation comprising substituted ßcyclodextrin
CO6390102A2 (en) ANITUMORAL COMBINATION INCLUDING AVE8062 AND SORAFENIB
MA32461B1 (en) Drondarone for the prevention of cardioversion
BR112013023575A8 (en) octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these
SMT201600243B (en) PHARMACEUTICAL COMPOSITIONS INCLUDING ANAKINRA WITHOUT CITRATE
CL2015001502A1 (en) Pharmaceutical composition comprising desloratadine and prendnisolone and use thereof.
UY33789A (en) COMBINATION THAT INCLUDES A FAMILY DERIVATIVE OF COMBRETASTATINAS AND CETUXIMAB
NI201300144A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF AN ORAL SUSPENSION INCLUDING A FLAVONOIC FRACTION AND XANTHANE GUM.
BR112013029778A2 (en) pharmaceutical composition comprising fexofenadine